热响应纳米炸弹产生反应性氧物种,用于协同抗癌疗法
Li Wang1, Mengzhen Yang1, Ruijing Gao1
1College of Chemistry & Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding 071002, China.
Journal of colloid and interface science
|February 20, 2025
概括
这项研究引入了新型纳米炸弹,可以产生活性氧物种 (ROS) 和氧化 (NO),以克服瘤缺氧并增强光动力疗法 (PDT),以改善癌症治疗.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 光动力疗法 (PDT) 通过诱导氧化损伤,显示出癌症治疗的前景.
- 瘤缺氧和短单点氧寿命限制PDT的疗效.
- 氧化 (NO) 气体治疗可以通过产生过氧化和过氧化的过氧化离子来增强PDT.
研究的目的:
- 开发一种新的纳米炸弹 (CaO2@LA-ICG@TD,CAI@TD) 用于协同的癌症治疗.
- 通过解决瘤缺氧和增加反应性氧物种 (ROS) 生成,增强光动力疗法 (PDT) 疗效.
- 研究CAI@TD在诱导癌细胞死亡和抑制瘤生长方面的潜力.
主要方法:
- 制造热控制的活性氧纳米炸弹 (CAI@TD).
- 用MDA-MB-231细胞进行体外研究,以评估ROS,过氧化和NO的产生.
- 评估细胞损伤,包括线粒体功能障碍,脂质过氧化和DNA碎片化.
- 使用异种移植瘤模型进行808nm激光照射的体内研究.
主要成果:
- CAI@TD成功释放了氧和过氧化,提高了PDT的疗效.
- 这些纳米炸弹通过线粒体损伤,脂质过氧化和DNA碎片化诱导了癌细胞的亡.
- 通过CAI@TD和激光照射观察到异种移植瘤生长的显著抑制.
结论:
- CAI@TD是一种有效的策略,用于产生高水平的ROS用于协同抗癌疗法.
- 这种方法提供了一个有希望的解决方案,以克服传统PDT在低氧瘤的局限性.
- 开发的纳米炸弹代表了癌症治疗开发的有希望的进步.
更多相关视频
相关概念视频
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Electron Transport Chain: Complex I and II
10.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


